SCHEMBL25665243

SCHEMBL25665243

COC(=O)C(N)CC(=O)c1ccccc1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.53
HSD17B10 Q99714 7/20 0.53
CFTR P13569 1/20 0.53
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 8/20 0.43
HIF1A Q16665 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
HPGD P15428 6/20 0.43
RCE1 Q9Y256 1/20 0.43
POLB P06746 1/20 0.42
TSHR P16473 2/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 1/20 0.41
GLA P06280 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30852342 1.00 ALDH1A1 (0.53) ALDH1A1HSD17B10CFTRKMT2AKDM4E
SCHEMBL9340040 1.00 ALDH1A1 (0.53) ALDH1A1HSD17B10CFTRKMT2AKDM4E
SCHEMBL30852281 0.86 ALDH1A1 (0.59) ALDH1A1HSD17B10CFTRKMT2AKDM4E
SCHEMBL4458686 0.86 ALDH1A1 (0.46) ALDH1A1HSD17B10CFTRKMT2AKDM4E
SCHEMBL27373840 0.84 ALDH1A1 (0.57) ALDH1A1HSD17B10CFTRKMT2AKDM4E
SCHEMBL27372220 0.84 ERCC5 (0.49) ALDH1A1KMT2AKDM4EHIF1ATDP1
SCHEMBL21309854 0.84 ALDH1A1 (0.49) ALDH1A1HSD17B10CFTRKMT2AKDM4E
SCHEMBL22873263 0.84 ALDH1A1 (0.49) ALDH1A1HSD17B10CFTRKMT2AKDM4E
SCHEMBL17483038 0.82 KDM4E (0.46) ALDH1A1HSD17B10CFTRKDM4EHIF1A
SCHEMBL17718270 0.82 KDM4E (0.46) ALDH1A1HSD17B10CFTRKDM4EHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098007-A1 Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light SOLIOME INC (US) 2026-04-09 US claimed
EP-4587007-A2 COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT Soliome, Inc. (US) 2025-07-23 EP claimed
CN-120019060-A Compounds and their use for filtering ultraviolet and/or high-energy visible light 索利奥美公司 2025-05-16 CN claimed
WO-2024059119-A2 COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT SOLIOME, INC. (US) 2024-03-21 WO claimed
US-20260098007-A1 Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light SOLIOME INC (US) 2026-04-09 US disclosed
EP-4587007-A2 COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT Soliome, Inc. (US) 2025-07-23 EP disclosed
CN-120019060-A Compounds and their use for filtering ultraviolet and/or high-energy visible light 索利奥美公司 2025-05-16 CN disclosed
WO-2024059119-A2 COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT SOLIOME, INC. (US) 2024-03-21 WO disclosed
US-20230181533-A1 FORMULATIONS WITH REDUCED OXIDATION GENENTECH INC (US) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181533-A1 FORMULATIONS WITH REDUCED OXIDATION PRDX5, PRDX3, LPO ALDH1A1 1133/4885HSD17B10 472/4885CFTR 1380/4885
US-20260098007-A1 Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light UGT8, UGT1A3, FUT5 ALDH1A1 217/4885HSD17B10 795/4885CFTR 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.